Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 02, 2023 11:58am

131 Views

Post# 35524201

RE:RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

Should read : ... " This decision of Eli Lilly to acquire such an early stage company for US$126 per share further demonstrates that Big Pharma is facing a looming patent cliff ...."

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023